Patent: 10,751,296
✉ Email this page to a colleague
Summary for Patent: 10,751,296
Title: | Curcuphenol compounds for increasing MHC-I expression |
Abstract: | Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies. |
Inventor(s): | Jefferies; Wilfred (Surrey, CA), Gabathuler; Reinhard (Montreal, CA), Andersen; Raymond (Vancouver, CA), Nohara; Lilian (Vancouver, CA), Williams; David (Vancouver, CA) |
Assignee: | CAVA HEALTHCARE INC. (CA) |
Application Number: | 15/415,291 |
Patent Claims: | see list of patent claims |
Details for Patent 10,751,296
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Aytu Bioscience, Inc. | PROSTASCINT | capromab pendetide | Injection | 103608 | 10/28/1996 | ⤷ Try a Trial | 2033-11-20 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2033-11-20 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2033-11-20 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-11-20 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-11-20 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2033-11-20 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2033-11-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |